Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 14/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.43 |
| ▸ | CDK2 | P24941 | 7/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 7/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5454686 | 0.90 | CCNA2 (0.53) | AURKACCNA2CDK2CCNA1HRH4 | |
| SCHEMBL5449349 | 0.87 | AURKA (0.51) | AURKACCNA2CDK2CCNA1F2 | |
| SCHEMBL5454557 | 0.85 | AURKA (0.55) | AURKACCNA2CDK2CCNA1AURKB | |
| SCHEMBL5459347 | 0.85 | AURKA (0.61) | AURKACCNA2CDK2CCNA1AURKB | |
| SCHEMBL5454247 | 0.84 | F2 (0.39) | AURKACDK2F2KMT2AHRH4 | |
| SCHEMBL5495916 | 0.83 | AURKA (0.55) | AURKACCNA2CDK2CCNA1AURKB | |
| SCHEMBL5451779 | 0.83 | AURKA (0.49) | AURKACCNA2CDK2CCNA1AURKB | |
| SCHEMBL5454345 | 0.82 | AURKA (0.53) | AURKACCNA2CDK2CCNA1F2 | |
| SCHEMBL5446062 | 0.82 | AURKA (0.49) | AURKACCNA2CDK2CCNA1AURKB | |
| SCHEMBL5454355 | 0.81 | AURKA (0.51) | AURKACCNA2CDK2CCNA1AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037790-A1 | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2007-02-15 | — | — | US | claimed |
| US-20070037790-A1 | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2007-02-15 | — | — | US | disclosed |
| EP-1608364-A1 | BICYCLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pharmacia Italia S.p.A. (IT) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004080457-A1 | BICYCLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037790-A1 | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K15, MAP3K7, MAP3K19 | AURKA 179/4885CCNA2 1123/4885CDK2 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.